The TCA cycle and tumorigenesis: the examples of fumarate hydratase and succinate dehydrogenase
- PMID:14708972
- DOI: 10.1080/07853890310018458
The TCA cycle and tumorigenesis: the examples of fumarate hydratase and succinate dehydrogenase
Abstract
It is well documented that disturbances in mitochondrial function are associated with rare childhood disorders and possibly with many common diseases of ageing, such as Parkinson's disease and dementia. There has also been increasing evidence linking mitochondrial dysfunction with tumorigenesis. Recently, heterozygous germline mutations in two enzymes of the Krebs tricarboxylic acid cycle (TCA cycle) have been shown to predispose individuals to tumours. The two enzymes, fumarate hydratase (FH) and succinate dehydrogenase (SDH), are ubiquitously expressed, playing a vital role in adenosine triphosphate (ATP) production through the mitochondrial respiratory chain. Germline mutations in FH are associated with leiomyomatosis and renal cell carcinoma, whilst SDH mutations are associated with predisposition to paraganglioma (PGL) and phaeochromocytoma (PCC). At present, there are few data to explain the pathway(s) involved in this predisposition to neoplasia through TCA cycle defects. We shall review the mechanisms by which mutations in FH and SDH might play a role in tumorigenesis. These include pseudo-hypoxia, mitochondrial dysfunction and impaired apoptosis, oxidative stress and anabolic drive. All of these mechanisms are currently poorly defined. To date, FH and SDH mutations have not been reported in non-familial leiomyomata, renal cancers, PCCs or PGLs. It remains entirely possible, however, that the underlying mechanisms of tumorigenesis in these sporadic tumours are the same as those in the Mendelian syndromes.
Similar articles
- Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations.Pollard PJ, Brière JJ, Alam NA, Barwell J, Barclay E, Wortham NC, Hunt T, Mitchell M, Olpin S, Moat SJ, Hargreaves IP, Heales SJ, Chung YL, Griffiths JR, Dalgleish A, McGrath JA, Gleeson MJ, Hodgson SV, Poulsom R, Rustin P, Tomlinson IP.Pollard PJ, et al.Hum Mol Genet. 2005 Aug 1;14(15):2231-9. doi: 10.1093/hmg/ddi227. Epub 2005 Jun 29.Hum Mol Genet. 2005.PMID:15987702
- Isocitrate dehydrogenase (IDH), succinate dehydrogenase (SDH), fumarate hydratase (FH): three players for one phenotype in cancer?Laurenti G, Tennant DA.Laurenti G, et al.Biochem Soc Trans. 2016 Aug 15;44(4):1111-6. doi: 10.1042/BST20160099.Biochem Soc Trans. 2016.PMID:27528759Review.
- Increased HIF1 alpha in SDH and FH deficient tumors does not cause microsatellite instability.Lehtonen HJ, Mäkinen MJ, Kiuru M, Laiho P, Herva R, van Minderhout I, Hogendoorn PC, Cornelisse C, Devilee P, Launonen V, Aaltonen LA.Lehtonen HJ, et al.Int J Cancer. 2007 Sep 15;121(6):1386-9. doi: 10.1002/ijc.22819.Int J Cancer. 2007.PMID:17520677
- Inactivation of SDH and FH cause loss of 5hmC and increased H3K9me3 in paraganglioma/pheochromocytoma and smooth muscle tumors.Hoekstra AS, de Graaff MA, Briaire-de Bruijn IH, Ras C, Seifar RM, van Minderhout I, Cornelisse CJ, Hogendoorn PC, Breuning MH, Suijker J, Korpershoek E, Kunst HP, Frizzell N, Devilee P, Bayley JP, Bovée JV.Hoekstra AS, et al.Oncotarget. 2015 Nov 17;6(36):38777-88. doi: 10.18632/oncotarget.6091.Oncotarget. 2015.PMID:26472283Free PMC article.
- Revisiting the TCA cycle: signaling to tumor formation.Raimundo N, Baysal BE, Shadel GS.Raimundo N, et al.Trends Mol Med. 2011 Nov;17(11):641-9. doi: 10.1016/j.molmed.2011.06.001. Epub 2011 Jul 20.Trends Mol Med. 2011.PMID:21764377Free PMC article.Review.
Cited by
- Cancer-derived extracellular succinate: a driver of cancer metastasis.Kuo CC, Wu JY, Wu KK.Kuo CC, et al.J Biomed Sci. 2022 Nov 7;29(1):93. doi: 10.1186/s12929-022-00878-z.J Biomed Sci. 2022.PMID:36344992Free PMC article.Review.
- Actuality of Warburg's views in our understanding of renal cancer metabolism.Godinot C, de Laplanche E, Hervouet E, Simonnet H.Godinot C, et al.J Bioenerg Biomembr. 2007 Jun;39(3):235-41. doi: 10.1007/s10863-007-9088-8.J Bioenerg Biomembr. 2007.PMID:17665292Review.
- Cancer as a metabolic disease: implications for novel therapeutics.Seyfried TN, Flores RE, Poff AM, D'Agostino DP.Seyfried TN, et al.Carcinogenesis. 2014 Mar;35(3):515-27. doi: 10.1093/carcin/bgt480. Epub 2013 Dec 16.Carcinogenesis. 2014.PMID:24343361Free PMC article.Review.
- Glioblastoma Stem-Like Cells, Metabolic Strategy to Kill a Challenging Target.Garnier D, Renoult O, Alves-Guerra MC, Paris F, Pecqueur C.Garnier D, et al.Front Oncol. 2019 Mar 6;9:118. doi: 10.3389/fonc.2019.00118. eCollection 2019.Front Oncol. 2019.PMID:30895167Free PMC article.Review.
- Metabolic Rewiring and the Characterization of Oncometabolites.Beyoğlu D, Idle JR.Beyoğlu D, et al.Cancers (Basel). 2021 Jun 10;13(12):2900. doi: 10.3390/cancers13122900.Cancers (Basel). 2021.PMID:34200553Free PMC article.Review.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous